vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. vTv Therapeutics' type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The Company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Show more
Type
Public
HQ
High Point, US
Founded
1998
Size (employees)
51 (est)
vTv Therapeutics was founded in 1998 and is headquartered in High Point, US
Report incorrect company information

vTv Therapeutics Office Locations

vTv Therapeutics has an office in High Point
High Point, US (HQ)
4170 Mendenhall Oaks Pkwy
Show all (1)
Report incorrect company information

vTv Therapeutics Financials and Metrics

vTv Therapeutics Financials

vTv Therapeutics's revenue was reported to be $291 k in FY, 2017
USD

Revenue (Q1, 2018)

2.1 m

EBIT (Q1, 2018)

(9.1 m)

Market capitalization (25-May-2018)

54.5 m

Closing share price (25-May-2018)

1.7

Cash (31-Mar-2018)

6.5 m

EV

74.1 m
vTv Therapeutics's current market capitalization is $54.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

519 k634 k291 k

Revenue growth, %

22%

General and administrative expense

9.1 m9.9 m11.3 m

R&D expense

27.2 m45 m39.6 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

133 k376 k182 k38 k30 k13 k2.1 m

General and administrative expense

2.4 m2.6 m2.7 m2.4 m2.8 m3 m2.3 m

R&D expense

6.6 m11.1 m12.1 m10.6 m11 m9.6 m8.9 m

Operating expense total

9.6 m13.9 m14.8 m13.6 m13.8 m12.6 m11.2 m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

88 m51.5 m11.8 m

Accounts Receivable

8 m

Inventories

1.1 m612 k

Current Assets

89.2 m52.1 m20.4 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

97 m75.5 m63.8 m51.1 m45.2 m32.5 m6.5 m

Accounts Receivable

210 k

Current Assets

97.8 m77.1 m64.3 m52.1 m45.9 m33.2 m9.5 m

PP&E

669 k545 k561 k493 k426 k374 k241 k
Annual
USDFY, 2015FY, 2016FY, 2017

Depreciation and Amortization

501 k265 k197 k

Inventories

5.5 m

Accounts Payable

2.9 m4.8 m2.4 m

Cash From Operating Activities

(36.9 m)(48.2 m)(44.6 m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Depreciation and Amortization

42 k

Accounts Payable

5.2 m8 m9.5 m10.2 m11.1 m(2.6 m)

Cash From Operating Activities

(5.4 m)

Cash From Investing Activities

12 k
USDY, 2018

EV/EBIT

-8.1 x

EV/CFO

-13.7 x
Show all financial metrics

vTv Therapeutics Operating Metrics

FY, 2016

Phase I Trials Products

2

Phase II Trials Products

2

Phase III Trials Products

1
Show all operating metrics
Report incorrect company information

vTv Therapeutics News and Updates

Report incorrect company information